<DOC>
	<DOCNO>NCT02628587</DOCNO>
	<brief_summary>Ischemic heart disease lead cause death disability develop country responsible third death person 35 year . The severe form ischemic heart disease sudden death acute coronary syndrome ( ACS ) . There evidence early optimal treatment ACS decrease mortality . Within optimal treatment , patient must receive reperfusion therapy mechanical pharmacologic treatment . In addition reperfusion treatment , antiplatelet therapy central part management . Aspirin plus P2Y12 inhibitor show decrease mortality . In country , clopidogrel accessible use P2Y12 inhibitor ; however , show wide variability response variability could influence different pharmacological , genetic environmental factor . Platelet reactivity measure aggregometry predicts major cardiovascular event ACS patient treat clopidogrel . Due frequent prescription , generic clopidogrel efficacy must evaluate . The purpose study compare platelet reactivity patient ACS receive clopidogrel generic versus patent .</brief_summary>
	<brief_title>Patent Versus Generic Clopidogrel Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>18 Diagnosis acute coronary syndrome Patients receive 300 mg Clopidogrel load single dose 75 mg daily Signature inform consent Active bleeding absolute contraindication antiplatelet use Chronic kidney disease creatinine clearance &lt; 30 ml / min Liver damage document elevated aspartate aminotransferase/alanine aspartate 2 time upper normal limit ( UNL ) and/or total bilirubin &gt; 2 time UNL Prescribed antiplatelet therapy , aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>